Elicio Therapeutics
Yahoo Finance • last month
Elicio Therapeutics drops 5%, prices $15M direct offering
* Elicio Therapeutics (ELTX [https://seekingalpha.com/symbol/ELTX]) priced [https://seekingalpha.com/pr/20571020-elicio-therapeutics-announces-pricing-of-15-million-registered-direct-offering] a $15M registered direct offering led by two... Full story
Yahoo Finance • last month
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced th... Full story
Yahoo Finance • last month
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. (“Elicio” or the “Company”) (NASDAQ: ELTX). Such investors are advised to contact Danielle Peyton at n... Full story
Yahoo Finance • 2 months ago
Top Biotech Gainers: QURE Rallies On AMT-130 Update, LNAI On Track, FTH Eyes Q4 Data, ELTX On Watch
(RTTNews) - Today's top gainers included uniQure, which rallied after the FDA softened its stance on the company's investigational gene therapy; Elicio Therapeutics, following encouraging treatment responses from its cancer vaccine in panc... Full story
Yahoo Finance • 2 months ago
Stocks Settle Sharply Higher as US-Iran Peace Deal Spurs Optimism
The S&P 500 Index ($SPX) (SPY) on Monday closed up +1.65%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.92%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +3.06%. June E-mini S&P futures (ESM26) rose +1.68%, and June E-m... Full story
Yahoo Finance • 2 months ago
Stocks Rally as US-Iran Peace Deal Sinks Oil and Bond Yields
The S&P 500 Index ($SPX) (SPY) today is up +1.67%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +1.24%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +2.79%. June E-mini S&P futures (ESM26) are up +1.72%, and June E-mini Nasdaq fut... Full story
Yahoo Finance • 2 months ago
Stocks Soar on US-Iran Peace Agreement
The S&P 500 Index ($SPX) (SPY) today is up +1.62%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +1.09%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +2.73%. June E-mini S&P futures (ESM26) are up +1.61%, and June E-mini Nasdaq fut... Full story
Yahoo Finance • 2 months ago
ELTX INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Elicio Therapeutics, Inc.
ATLANTA, June 15, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Elicio Therapeutics, Inc. (“Elicio” or the “Company”) (NASDAQ: ELTX) complied with federal securities laws. On June 15, 2026, Elicio announced that... Full story
Yahoo Finance • 2 months ago
Pre-Market Movers: BYAH, LXEO, ELTX Swing Big
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday. Price swings ahead of the opening bell are being driven by clinical trial and regulatory updates, as well as trial endpoint misses. In the Green - Prem... Full story
Yahoo Finance • 5 months ago
Elicio Therapeutics reports FY GAAP EPS of -$2.58
* Elicio Therapeutics press release [https://seekingalpha.com/pr/20435956-elicio-therapeutics-reports-full-year-2025-financial-results-and-provides-corporate-updates] (ELTX [https://seekingalpha.com/symbol/ELTX]): FY GAAP EPS of -$2.58.... Full story
Yahoo Finance • 9 months ago
Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today annou... Full story
- CMC
Mentioned:
Yahoo Finance • 9 months ago
Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), fewer disease progressions and deaths than projected have been observed as of November 6, 2025. Based on 2:1 randomiz... Full story
Yahoo Finance • 9 months ago
KRAS Inhibitors Market to Witness Explosive Growth at a CAGR of 35% During the Forecast Period (2025–2034) Amid Expanding Therapeutic Landscape | DelveInsight
DelveInsight Business Research LLP The KRAS inhibitors market is expected to experience substantial growth, driven by rising cancer incidence, improved treatment access, and a robust pipeline including Olomorasib (Eli Lilly), MK-1084 (Mer... Full story
Yahoo Finance • 10 months ago
Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor (“CPI”) in the neoadjuvant setting Trial is anticipated to begin enrolling in H1’2026 BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeut... Full story
- T
Mentioned:
Yahoo Finance • 11 months ago
Elicio Therapeutics Reports Inducement Grants
BOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today anno... Full story
- T
Mentioned:
Yahoo Finance • last year
Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients
At extended median follow-up of 19.7 months, median overall survival (“OS”) increased from 16.33 to 28.94 months Clinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS (“mKRAS”) induced by ELI-00277% re... Full story
Yahoo Finance • last year
Elicio (ELTX) Q2 Loss Beats Estimates
Key Points Elicio Therapeutics (NASDAQ:ELTX) reported a net loss per share of $0.66 (GAAP) for the second quarter, beating the analyst estimate of $(0.69) (GAAP). Research and development (R&D) expenses (GAAP) decreased 14.6% year-over-ye... Full story
Yahoo Finance • last year
Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy’ Ratings
Syringe and red cross by Stadratte via iStock Cancer remains one of the most relentless challenges in modern medicine. In 2025, over 2 million new cancer cases are expected to be diagnosed in the United States. More than 618,000 people wi... Full story
Yahoo Finance • last year
Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer
BOSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today annou... Full story
Yahoo Finance • last year
Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires
BOSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, to... Full story